Age Related Macular Degeneration (AMD) Market By Drug Type (Aflibercept, Ranibizumab, Others), By Disease Type (Wet Age Related Macular Degeneration (AMD), Dry Age Related Macular Degeneration (AMD)), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2023-2032
The global age-related macular degeneration (AMD) market was valued at $9.4 billion in 2022 and is projected to reach $15.4 billion by 2032, growing at a CAGR of 5% from 2023 to 2032. Age-related macular degeneration (AMD) is a common eye condition that affects millions of people across the globe, particularly those aged 50 and above. It is a progressive disease that affects the macula, which is the central part of the retina responsible for sharp, central vision. The two main types of age-related macular degeneration (AMD) are dry and wet age-related macular degeneration (AMD). Dry age-related macular degeneration (AMD), the most common type of age-related macular degeneration (AMD), occurs when the light-sensitive cells in the macula break down and die over time, causing a gradual loss of central vision. Wet age-related macular degeneration (AMD), a less common but more severe form of age-related macular degeneration (AMD), occurs when abnormal blood vessels grow beneath the retina and leak fluid, blood, and protein, causing scarring and damage to the macula.
The key factors that drive the growth of age-related macular degeneration (AMD) market are increase in the geriatric population, surge in demand for effective treatment options, and technological advancement. For instance, according to the 2022 factsheet of World Health Organization, by 2030, 1 in 6 people in the world is projected to be aged 60 years or over. By 2050, the world population of people aged 60 years and older is projected to be 2.1 billion. The number of people aged 80 years or older is expected to reach 426 million by 2050. In addition, rise in the demand for age related macular degeneration drugs for the treatment dry age-related macular degeneration (AMD) across the world further boost the growth of the market.
However, high cost associated with age related macular degeneration drugs is projected to impede the market growth in upcoming years. On the contrary, increase in R&D activities in age-related macular degeneration (AMD) treatment, and latest product approvals are expected to provide lucrative opportunities for the growth of the market in the near future.
The age-related macular degeneration (AMD) market is segmented into drug type, disease type, distribution channels and region. On the basis of drug type, the market is categorized into aflibercept, ranibizumab and others. On the basis of disease type, the market is bifurcated into dry age-related macular degeneration (AMD) and wet age-related macular degeneration (AMD). On the basis of distribution channels, the market is segmented into hospital pharmacy, retail pharmacy and online pharmacy. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).
Major key players that operate in the global age-related macular degeneration (AMD) market are Regeneron Pharmaceuticals Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Biogen, Bayer AG, Bausch Health Companies Inc, Coherus Biosciences Inc, Sanofi, Apellis Pharmaceuticals and Ionis Pharmaceuticals, Inc.
Key Benefits For StakeholdersThis report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the age related macular degeneration (amd) market analysis from 2022 to 2032 to identify the prevailing age related macular degeneration (amd) market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the age related macular degeneration (amd) market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global age related macular degeneration (amd) market trends, key players, market segments, application areas, and market growth strategies.
Key Market SegmentsBy Drug TypeAflibercept
Ranibizumab
Others
By Disease TypeWet Age Related Macular Degeneration (AMD)
Dry Age Related Macular Degeneration (AMD)
By Distribution ChannelHospital Pharmacy
Retail Pharmacy
Online Pharmacy
By RegionNorth America
U.S.
Canada
Mexico
Europe
France
Germany
Italy
Spain
UK
Rest of Europe
Asia-Pacific
China
Japan
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
F. Hoffmann-La Roche Ltd.
Coherus Biosciences Inc
Biogen
Regeneron Pharmaceuticals Inc.
Ionis Pharmaceuticals, Inc.
Novartis AG
Bayer AG
Bausch Health Companies Inc.
Apellis Pharmaceuticals Inc.
Sanofi S.A.
Please Note: It will take 7-10 business days to complete the report upon order confirmation.